falsefalse

Leukemia & Lymphoma: A Review of Data from the ASCO 2022 and EHA 2022 Meetings - Episode 2

Lymphomas Trial Data From the ASCO 2022 and EHA 2022 Annual Meetings

, ,

Shared insight from expert oncologists on key clinical trial data in lymphomas from the ASCO 2022 and EHA 2022 Annual Meetings.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Data from the following clinical trials are discussed:

    • ASCO 7521: ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
    • EHA P1120: The Efficacy and Safety of Zanubrutinib and Dexamethasone in Symptomatic Waldenstrom Macroglobulinemia
    • EHA P1160: Results of a Phase 2 Expanded Access Study of Zanubrutinib in Patients with Waldenstrom Macroglobulinemia
    • ASCO 7510: Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial
    • ASCO 7511: Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL
    • ASCO 7524: Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial
    x